keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/29322401/is-it-possible-to-cure-the-symptoms-of-the-overactive-bladder-in-women
#1
Jan Krhut, Alois Martan, Roman Zachoval, Tomas Hanus, Lukas Horcicka, Kamil Svabík, Peter Zvara
PURPOSE: To evaluate the feasibility of discontinuing treatment with mirabegron once symptoms have subsided in patients with overactive bladder (OAB). METHODS: The present study evaluated a total of 159 female OAB patients (age 62.9 ± 12.36), each of which were prescribed 50 mg/day mirabegron (Time point 1-T1). Data obtained from voiding diaries and patient-reported outcome variables were assessed during follow-up visits at months 1, 3, 6, 12, 18 (T2), and 21 (T4)...
January 10, 2018: International Urology and Nephrology
https://www.readbyqxmd.com/read/29319477/publicly-funded-overactive-bladder-drug-treatment-patterns-in-ontario-over-15-years-an-ecologic-study
#2
Mina Tadrous, Dean Elterman, Wayne Khuu, Muhammad M Mamdani, David N Juurlink, Tara Gomes
INTRODUCTION: Medication is an important option for patients with overactive bladder (OAB), with four different drugs approved over the last 10 years including the first non-anticholinergic treatment, mirabegron. We set out to describe the number and rate of users of medication for the management of OAB over the last 15 years among residents of Ontario, Canada covered by the public drug programs. METHODS: We conducted a population-based, repeated cross-sectional study examining quarterly publically-funded prescription claims for OAB medications from January 2000 to June 2016 in Ontario, Canada...
December 22, 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29287033/impact-of-new-medications-and-4-generic-programs-on-overactive-bladder-treatment-among-older-adults-in-the-united-states-2000-2015
#3
Alan C Kinlaw, Michele Jonsson Funk, Mitchell M Conover, Virginia Pate, Alayne D Markland, Jennifer M Wu
BACKGROUND: Despite several new medications being Food and Drug Administration-approved for overactive bladder (OAB) and new prescription drug payment programs, there are limited population-based data regarding OAB medication use among older adults. OBJECTIVES: To examine: (1) impacts of new medications and $4 generic programs on time trends for OAB-related medication dispensing for older adults in the United States; (2) differences by age and sex; and (3) temporal changes in OAB-related medication payments...
December 28, 2017: Medical Care
https://www.readbyqxmd.com/read/29283084/mirabegron-as-adjuvant-treatment-for-patients-with-interstitial-cystitis-bladder-pain-syndrome
#4
Michael Di Lena, Victoria Tolls, Kerri-Lynn Kelly, J Curtis Nickel
INTRODUCTION: Interstitial cystitis/bladder pain syndrome (IC/BPS) patients represent a heterogeneous group with pain and urinary storage symptoms and varying responses to current treatment options. The novel beta-3 agonist, mirabegron, has been shown to improve storage symptoms of patients with bladder overactivity; however, its effect on symptoms in the IC/BPS population has yet to be studied. METHODS: Patients diagnosed at a single IC centre with IC/BPS undergoing standard therapy were treated with additional daily mirabegron 25 mg and seen in followup post-treatment...
December 22, 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29260636/effective-treatment-of-neurogenic-detrusor-overactivity-in-multiple-sclerosis-patients-using-desmopressin-and-mirabegron
#5
Athanasios Zachariou, Maria Filiponi, Dimitrios Baltogiannis, John Giannakis, Fotios Dimitriadis, Panagiota Tsounapi, Atsushi Takenaka, Nikolaos Sofikitis
INTRODUCTION: Multiple sclerosis (MS) is the commonest progressive neurological disease affecting young people. With advancing disease, management of neurogenic detrusor overactivity (NDO) based on antimuscarinics may prove inadequate and if based on botulinum toxin, may necessitate clean intermittent self-catheterization. The aim of the study was to evaluate the effectiveness of combined mirabegron and desmopressin administration in the treatment of NDO in patients with MS. MATERIALS AND METHODS: Sixty patients diagnosed with MS and NDO were evaluated...
December 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/29243229/mirabegron-potential-off-target-effects-and-uses-beyond-the-bladder
#6
REVIEW
Nodi Dehvari, Edilson Dantas da Silva Junior, Tore Bengtsson, Dana S Hutchinson
The ®3 -adrenoceptor was initially an attractive target by several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose handling) in animal models of obesity and type 2 diabetes. However, several drugs acting at the β3 -adrenoceptor failed in clinical trials. This was thought to be due to their lack of efficacy at the human receptor. Recently mirabegron, a ®3 -adrenoceptor agonist with human efficacy, was approved in North America, Europe, Japan and Australia for the treatment of overactive bladder syndrome...
December 15, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29205506/systematic-review-and-meta-analysis-on-the-efficacy-and-tolerability-of-mirabegron-for-the-treatment-of-storage-lower-urinary-tract-symptoms-overactive-bladder-comparison-with-placebo-and-tolterodine
#7
REVIEW
Arcangelo Sebastianelli, Giorgio I Russo, Steven A Kaplan, Kevin T McVary, Ignacio Moncada, Stavros Gravas, Christopher Chapple, Giuseppe Morgia, Sergio Serni, Mauro Gacci
A systematic review and meta-analysis was carried out to evaluate the efficacy and safety of mirabegron 50 mg and 100 mg in the treatment of storage lower urinary tract symptoms/overactive bladder in comparison with a placebo and tolterodine 4 mg. A total of 491 articles were collected and eight randomized studies were identified as eligible for this meta-analysis. Overall, eight trials were included in the meta-analysis evaluating 10 248 patients. Mirabegron at both doses of 50 mg and 100 mg, and and tolterodine 4 mg were significantly associated with the reduction of incontinence episodes per 24 h, reduction of mean number of micturitions per 24 h, increase of voided volume and reduction of urgency episodes per 24 h, compared to a placebo...
December 3, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29196071/percutaneous-tibial-nerve-stimulation-in-the-office-setting-real-world-experience-of-over-100-patients
#8
Evan R Sirls, Kim A Killinger, Judith A Boura, Kenneth M Peters
OBJECTIVE: To examine the outcomes and compliance with percutaneous tibial nerve stimulation (PTNS) for overactive bladder symptoms (OAB). METHODS: Adults that had PTNS from 6/30/2011 to 10/8/2015 were retrospectively reviewed for demographics, co-pay, travel distance, employment status, history, symptoms, and treatments used before, during and after PTNS. Pearson's Chi-square, Fisher's exact, Wilcoxon rank and paired t tests were performed. RESULTS: Of 113 patients (mean age 75 ± 12 years), most were women (65...
November 28, 2017: Urology
https://www.readbyqxmd.com/read/29164523/identification-of-uridine-5-diphosphate-glucuronosyltransferases-responsible-for-the-glucuronidation-of-mirabegron-a-potent-and-selective-%C3%AE-3-adrenoceptor-agonist-in-human-liver-microsomes
#9
Kentaro Konishi, Daisuke Tenmizu, Shin Takusagawa
BACKGROUND AND OBJECTIVES: Mirabegron is cleared by multiple mechanisms, including drug-metabolizing enzymes. One of the most important clearance pathways is direct glucuronidation. In humans, M11 (O-glucuronide), M13 (carbamoyl-glucuronide), and M14 (N-glucuronide) have been identified, of which M11 is one of the major metabolites in human plasma. The objective of this study was to identify the uridine 5'-diphosphate (UDP)-glucuronosyltransferase (UGT) isoform responsible for the direct glucuronidation of mirabegron using human liver microsomes (HLMs) and recombinant human UGTs (rhUGTs)...
November 21, 2017: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29134621/replication-of-mini-sentinel-study-assessing-mirabegron-and-cardiovascular-risk-in-non-mini-sentinel-databases
#10
Jason C Simeone, Beth L Nordstrom, Kwame Appenteng, Samuel Huse, Milbhor D'Silva
BACKGROUND: In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) and stroke with use of mirabegron, indicated for the treatment of overactive bladder (OAB), compared with oxybutynin. PURPOSE: To replicate the FDA M-S analysis of mirabegron using datasets that did not contribute to the M-S program. METHODS: IMS PharMetrics Plus and Truven MarketScan claims data from 2012-2015 were converted to the M-S Common Data Model...
November 13, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/28986184/no-353-treatments-for-overactive-bladder-focus-on-pharmacotherapy-an-addendum
#11
Roxana Geoffrion
OBJECTIVE: This technical update addendum reviews success rates and comparative evidence of the anticholinergic fesoterodine, as well as mechanism of action, safety profile, success rates, and comparative evidence of the β3 agonist mirabegron in the treatment of non-neurogenic overactive bladder syndrome (OAB). This adds to OAB pharmacotherapy recommendations initially published in 2012. INTENDED USERS: Residents and other trainees, primary care practitioners, gynaecologists, urologists, urogynaecologists, and other health care providers who assess, counsel, and treat women with OAB...
October 3, 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/28954464/meta-analysis-of-the-efficacy-and-safety-of-mirabegron-add-on-therapy-to-solifenacin-for-overactive-bladder
#12
Yankai Xu, Ruihua Liu, Chu Liu, Yuanshan Cui, Zhenli Gao
PURPOSE: We performed a meta-analysis to evaluate the efficacy and safety of mirabegron add-on therapy to solifenacin for patients with overactive bladder (OAB). METHODS: We conducted a systematic literature review to identify all randomized, double-blind, controlled trials (RCTs) of this combination (mirabegron and solifenacin) for OAB. Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials were searched. A manual search was also performed to investigate relevant references from the retrieved studies...
September 2017: International Neurourology Journal
https://www.readbyqxmd.com/read/28916436/treating-overactive-bladder-in-older-patients-with-a-combination-of-mirabegron-and-solifenacin-a-prespecified-analysis-from-the-beside-study
#13
William Gibson, Scott MacDiarmid, Moses Huang, Emad Siddiqui, Matthias Stölzel, Nurul Choudhury, Marcus J Drake
BACKGROUND: The BESIDE study demonstrated that combination therapy (mirabegron and solifenacin 5mg) improved overactive bladder symptoms versus solifenacin 5mg or 10mg, and was well tolerated. OBJECTIVE: To ensure efficacy and safety is maintained in older patients (>65 yr), who usually experience greater symptom severity and comorbidities, a prespecified subanalysis stratified by age group was conducted. DESIGN, SETTING, AND PARTICIPANTS: Patients remaining incontinent (≥1 episode during 3-d diary) following 4-wk single-blind daily solifenacin 5mg were randomized 1:1:1 to a daily double-blind combination (solifenacin 5mg and mirabegron 25mg, increased to 50mg at wk 4), solifenacin 5mg or 10mg for 12 wk...
September 12, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28906080/persistence-and-adherence-with-mirabegron-vs-antimuscarinics-in-overactive-bladder-retrospective-analysis-of-a-uk-general-practice-prescription-database
#14
Adrian S Wagg, Steve Foley, John Peters, Jameel Nazir, Leanne Kool-Houweling, Ludmila Scrine
INTRODUCTION AND OBJECTIVES: Persistence with antimuscarinic (AM) drugs prescribed for overactive bladder (OAB) is poor. This study aimed to compare persistence and adherence with the beta-3-adrenoceptor agonist mirabegron (MIR) vs AMs over 12 months. PATIENTS AND METHODS: This retrospective cohort analysis included patients aged ≥18 years who were prescribed MIR, or any AM. A 12-month look-back was used to assess inclusion eligibility. The primary end-point was persistence, defined as time to first discontinuation of index drug, during 1 year follow-up...
October 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28901041/safety-and-effectiveness-of-mirabegron-in-patients-with-overactive-bladder-aged-%C3%A2-75%C3%A2-years-analysis-of-a-japanese-post-marketing-study
#15
Masaki Yoshida, Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi, Kentarou Kuroishi
OBJECTIVES: A 12-week post-marketing study was conducted to provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with mirabegron. This post-hoc analysis focused on safety and effectiveness of mirabegron in patients aged ≥75 versus <75 years. METHODS: Incidence of adverse drug reactions (ADR) was assessed following 12 weeks' mirabegron treatment. Overactive Bladder Symptom Score (OABSS) and International-Prostate Symptom Score Quality of Life (I-PSS QoL) were completed at baseline and at the end of treatment (EoT)...
September 12, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28889761/safety-issues-associated-with-using-medication-to-treat-overactive-bladder
#16
REVIEW
George Araklitis, Linda Cardozo
The mainstay of overactive bladder treatment is the use of anticholinergic medication with its common side effects well known. This review focused on three less well-known safety issues when treating OAB. Areas covered: Patients with increased anticholinergic load are at risk of cognitive decline, dementia or even death. The elderly are particularly at risk due to polypharmacy. Botulinum toxin carries the risk of high urinary residuals, urinary tract infection and need to self catheterise. The use of vaginal oestrogens may improve OAB symptoms, but there is concern in those with a history of breast cancer...
November 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28833621/persistence-and-adherence-to-overactive-bladder-medications-in-japan-a-large-nationwide-real-world-analysis
#17
Daisuke Kato, Satoshi Uno, James Van Schyndle, Alan Fan, Tomomi Kimura
OBJECTIVES: To evaluate persistence and adherence to mirabegron and antimuscarinics in Japan using data from two administrative databases. METHODS: The present retrospective study evaluated insurance claims for employees and dependents aged ≤75 years, and pharmacy claims for outpatients. From October 2012 to September 2014, new users of mirabegron or five individual antimuscarinics indicated for overactive bladder in Japan (fesoterodine, imidafenacin, propiverine, solifenacin and tolterodine) were identified and followed for 1 year...
August 22, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28814193/sirolimus-and-mirabegron-interaction-in-a-hematopoietic-cell-transplant-patient
#18
Jeff A Engle, Christina Fair
Purpose Hematopoietic cell transplant patients are exposed to numerous classes of medications. Transplant practitioners must vigilantly monitor for drug interactions especially involving immunosuppressants. We report a hematopoietic cell transplant patient receiving sirolimus who developed supratherapeutic serum concentrations after initiating mirabegron. Summary A 31-year-old, 98 kg female received a second umbilical cord blood transplant four years after the first transplant for relapsed acute myeloid leukemia...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28805473/the-impact-of-persistence-with-mirabegron-usage-vs-switching-to-onabotulinumtoxina-on-healthcare-costs-and-resource-utilization-in-patients-with-overactive-bladder-in-the-united-states
#19
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, David Walker, Katherine Gooch
AIMS: To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the US who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. MATERIALS AND METHODS: A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters)...
September 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28762672/safety-efficacy-and-persistence-of-long-term-mirabegron-treatment-for-overactive-bladder-in-the-daily-clinical-setting-interim-1-year-report-from-a-japanese-post-marketing-surveillance-study
#20
Daisuke Kato, Hiromi Tabuchi, Satoshi Uno
OBJECTIVES: To report interim 1-year results from a 3-year surveillance study evaluating safety, efficacy, and persistence of long-term mirabegron for overactive bladder (OAB). METHODS: Patients starting treatment with mirabegron for urinary urgency, daytime frequency, and urgency incontinence associated with OAB were registered and followed up for 3 years. Data were collected on adverse drug reactions (ADR), changes in OAB symptoms, changes in Overactive Bladder Symptom Score (OABSS), and treatment discontinuations...
August 1, 2017: Lower Urinary Tract Symptoms
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"